Search for other papers by A V Dreval in
Google Scholar
PubMed
Search for other papers by I V Trigolosova in
Google Scholar
PubMed
Search for other papers by I V Misnikova in
Google Scholar
PubMed
Search for other papers by Y A Kovalyova in
Google Scholar
PubMed
Search for other papers by R S Tishenina in
Google Scholar
PubMed
Search for other papers by I A Barsukov in
Google Scholar
PubMed
Search for other papers by A V Vinogradova in
Google Scholar
PubMed
Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
outpatient clinic of the Moscow Regional Clinical Research State Institute underwent an extensive evaluation, which included measurement of height, weight and blood pressure. Those patients who had not previously been diagnosed with DM underwent an oral
Search for other papers by Julie M Silverstein in
Google Scholar
PubMed
Panel of 1993, the earliest definition considered controlled acromegaly to be GH levels <2.0 ng/ml after an oral glucose tolerance test (OGTT) and serum GH levels <2.5 ng/ml, as well as the normalization of circulating levels of free and total IGF1 (24
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
pegvisomant both improve insulin sensitivity ( 6 ), glucose metabolism may improve or worsen when patients are treated with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide ( 7 , 8 , 9 , 10 ). Pasireotide is a somatostatin
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
Search for other papers by Richard P Steeds in
Google Scholar
PubMed
Search for other papers by Vandana Sagar in
Google Scholar
PubMed
Search for other papers by Shishir Shetty in
Google Scholar
PubMed
Search for other papers by Tessa Oelofse in
Google Scholar
PubMed
Search for other papers by Harjot Singh in
Google Scholar
PubMed
Search for other papers by Raheel Ahmad in
Google Scholar
PubMed
Search for other papers by Elizabeth Bradley in
Google Scholar
PubMed
Search for other papers by Rachel Moore in
Google Scholar
PubMed
Search for other papers by Suzanne Vickrage in
Google Scholar
PubMed
Search for other papers by Stacey Smith in
Google Scholar
PubMed
Search for other papers by Ivan Yim in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
Search for other papers by Yasir S Elhassan in
Google Scholar
PubMed
Search for other papers by Hema Venkataraman in
Google Scholar
PubMed
Search for other papers by John Ayuk in
Google Scholar
PubMed
Search for other papers by Stephen Rooney in
Google Scholar
PubMed
Department of Hepatology and Liver Transplantation, University Hospitals Birmingham (Queen Elizabeth), NHS Hospitals Foundation Trust, Birmingham, UK
Search for other papers by Tahir Shah in
Google Scholar
PubMed
efficacy in managing symptoms. At this point, the frequency of injections should be increased from the standard 4 weekly to 3- or 2-weekly. Short-acting octreotide given subcutaneously 3 times daily can provide additional relief. If these measures are not
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by David A Cano in
Google Scholar
PubMed
Search for other papers by Eva Venegas-Moreno in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Elena Dios in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Alvaro Flores-Martínez in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Alfonso Soto-Moreno in
Google Scholar
PubMed
(surgery, medical therapy, radiotherapy) and the magnitude of hormonal responses to treatment with SSA (including % reduction in IGF-1 from baseline; GH levels on an oral glucose tolerance test), where relevant. Inclusion criteria We undertook a
Search for other papers by Rimesh Pal in
Google Scholar
PubMed
Search for other papers by Sanjay Kumar Bhadada in
Google Scholar
PubMed
Search for other papers by Awesh Singhare in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Search for other papers by Sadishkumar Kamalanathan in
Google Scholar
PubMed
Search for other papers by Manoj Chadha in
Google Scholar
PubMed
Search for other papers by Phulrenu Chauhan in
Google Scholar
PubMed
Search for other papers by Ashwani Sood in
Google Scholar
PubMed
Search for other papers by Vandana Dhiman in
Google Scholar
PubMed
Search for other papers by Dinesh Chandra Sharma in
Google Scholar
PubMed
Search for other papers by Uma Nahar Saikia in
Google Scholar
PubMed
Search for other papers by Debajyoti Chatterjee in
Google Scholar
PubMed
Search for other papers by Vikas Agashe in
Google Scholar
PubMed
with oral phosphate and calcitriol supplementation. Phosphate was supplemented in the form of sodium phosphate granules at a starting dose of 20 mg/kg/day in four to five divided doses which was gradually hiked up to a dose of 50 mg/kg/day in an attempt
Search for other papers by Sondra O’Callaghan in
Google Scholar
PubMed
Search for other papers by Hanford Yau in
Google Scholar
PubMed
successful, can slow progression to a state of hypercalcemia. Certainly, reducing exogenous influences on calcium burden are paramount. This can be achieved by removing calcium supplements orally, parenterally, and in dialysate. Low calcium or calcium
Search for other papers by E T Aristizabal Prada in
Google Scholar
PubMed
Search for other papers by C J Auernhammer in
Google Scholar
PubMed
analogues Treatment of NET cells in vitro with a combination of the mTORC1 inhibitor rapamycin or everolimus plus the somatostatin analogue octreotide has caused controversial results in different models. The combination of mTORC1 inhibitors plus
1st Department of Propaupaedic Internal Medicine, Endocrine Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Kosmas Daskalakis in
Google Scholar
PubMed
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Evanthia Kassi in
Google Scholar
PubMed
Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Search for other papers by Denise Kolomodi in
Google Scholar
PubMed
Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry, UK
Centre of Applied Biological & Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, Coventry, UK
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
, 13 ). Importantly, MTTs with everolimus and sunitinib have distinct SE profiles, which differ from those of cytotoxic chemotherapies. The continual and occasionally prolonged nature of orally administered MTT leads to new challenges in their
Search for other papers by Marloes Emous in
Google Scholar
PubMed
Search for other papers by Merel van den Broek in
Google Scholar
PubMed
Search for other papers by Ragnhild B Wijma in
Google Scholar
PubMed
Search for other papers by Loek J M de Heide in
Google Scholar
PubMed
Search for other papers by Gertjan van Dijk in
Google Scholar
PubMed
Search for other papers by Anke Laskewitz in
Google Scholar
PubMed
Search for other papers by Erik Totté in
Google Scholar
PubMed
Search for other papers by Bruce H R Wolffenbuttel in
Google Scholar
PubMed
Department of Endocrinology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
Search for other papers by André P van Beek in
Google Scholar
PubMed
provide more insight into the pathophysiology, for instance, by providing a standardized stimulus or meal in a laboratory while performing extensive hormone analyses. Older studies have used the oral glucose challenge as standardized stimulus, but nowadays